CN103804195B - A kind of method synthesizing tafluprost - Google Patents

A kind of method synthesizing tafluprost Download PDF

Info

Publication number
CN103804195B
CN103804195B CN201410037416.0A CN201410037416A CN103804195B CN 103804195 B CN103804195 B CN 103804195B CN 201410037416 A CN201410037416 A CN 201410037416A CN 103804195 B CN103804195 B CN 103804195B
Authority
CN
China
Prior art keywords
compound
formula
temperature
acid
response time
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201410037416.0A
Other languages
Chinese (zh)
Other versions
CN103804195A (en
Inventor
杨波
彭乐
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chak Enyuan (tianjin) Pharmaceutical Co Ltd
Original Assignee
Chak Enyuan (tianjin) Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chak Enyuan (tianjin) Pharmaceutical Co Ltd filed Critical Chak Enyuan (tianjin) Pharmaceutical Co Ltd
Priority to CN201410037416.0A priority Critical patent/CN103804195B/en
Publication of CN103804195A publication Critical patent/CN103804195A/en
Application granted granted Critical
Publication of CN103804195B publication Critical patent/CN103804195B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0025—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing keto groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/307—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by introduction of halogen; by substitution of halogen atoms by other halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/317—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by splitting-off hydrogen or functional groups; by hydrogenolysis of functional groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C07C69/736—Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Is the present invention with Corey? Lactone reduces through DIBAL after suitably protecting; Wittig reacts; carboxy protective; Swern oxidation obtains a versatile intermediates compound 1; with intermediate 1 for raw material; tafluprost (being left out deprotection steps, fluoride is final step) and multiple midbody product it is obtained by reacting through several steps. Intermediate 1 can synthesize other multiple prostatitis element analog by connecting from different ω chains, such as MISOPROSTOL prostatitis element, travoprost, latanoprost etc. 2～4 synthesis that can also be used for other 16-phenoxy group prostatitis element.

Description

A kind of method synthesizing tafluprost
Technical field
The present invention relates to the new method of a kind of tafluprost and the midbody compound related in new method.
Background technology
The tafluprost that Merk company releases is a kind of Novel prostate element derivant, it it is the first prostaglandin analogue eye drop without preservative, for treating open angle glaucoma, main mechanism is to promote that aqueous humor is discharged through uveal scleral approach, thus reducing intraocular pressure.
It is raw material that the synthesis of tafluprost is generally adopted CoreyLactone; oxidized; connect ω chain; fluoride; DIBAL reduces; Wittig reaction forming α chain, esterification and corresponding protection and deprotection steps obtain final products, such as TetrahedronLetters45 (2004) 1527-1529
This route first connects ω chain, adopts the method being conventionally synthesized PG to obtain tafluprost after 15 fluorides again. Because current only tafluprost one of prostaglandin product that ω chain is containing the double; two fluorine in 15-position, so the intermediate that this route is after fluorination step is simply possible to use in the production of tafluprost.
Summary of the invention
Consider that major part PGF and PGE series derivates is distinctive in that ω chain; so list of references CollCzechChemComm (1997) 62(8 of the present invention) 1325; reduce through DIBAL after suitably protecting with CoreyLactone; Wittig reacts; carboxy protective, Swern oxidation obtains a versatile intermediates--compound 1, as raw material; it is obtained by reacting tafluprost (being left out deprotection steps, fluoride is final step) through several steps. Compound 1 can synthesize other multiple prostatitis element analog by connecting from different ω chains, such as MISOPROSTOL prostatitis element, travoprost, latanoprost etc. 2～4 synthesis that can also be used for other 16-phenoxy group prostatitis element.
The present invention is achieved by the following technical solutions:
Formula 2 compound:
The preparation method of formula 2 compound:
Preferably,
With compound 1 for raw material, by Horner-Wadsworth-Emmons reaction forming side chain synthesis type 2 compound under alkali condition, alkali used by synthetic reaction may select butyl lithium, t-BuOK, LiOH H2O or Et3N/LiCl, solvent may select dichloromethane, toluene or oxolane.
Preferably, the mol ratio of side chain and aldehyde is 0.8:1～2.5:1, and temperature is-20～80 DEG C, 1～24 hour response time.
It is preferred that, the mol ratio of side chain and aldehyde is 1.2:1, and temperature is 20～30 DEG C.
Formula 3 compound
The preparation method of formula 3 compound:
Formula 2 compound is sloughed THP in acid condition and is protected base to obtain formula 3 compound, and acid can be selected for hydrochloric acid, acetic acid, p-methyl benzenesulfonic acid or trifluoroacetic acid; Solvent can be selected for methanol, ethanol, isopropanol or oxolane.
Preferably, the molar ratio of formula 2 compound and acid is 0.1:1～0.6:1, and temperature is 0～80 DEG C, 1～24 hour response time. It is preferred that reaction temperature is 30 DEG C.
Formula 4 compound
The preparation method of formula 4 compound:
Formula 3 compound passes through acetylization reaction synthesis type 4 compound, and acetylation reagent can be selected for acetic anhydride or chloroacetic chloride; Solvent can use pyridine, dichloromethane, dichloroethanes, chloroform, toluene or acetonitrile.
Preferably, the mol ratio of acetylation reagent and formula 3 compound is 0.8:1～3:1, and temperature is-20～80 DEG C, 0.5～24 hour response time.
Formula 5 compound
The preparation method of formula 5 compound:
Formula 4 compound through fluorination reaction synthesis type 5 compound, the optional Deoxofluor(of fluorination reagent is double; two-(2-methoxy ethyl) amido sulfur trifluoride), sulfur trifluoride or sulfur trifluoride morpholine; Solvent can be selected for dichloromethane, chloroform or toluene etc.
Preferably, fluorination reagent and the molar ratio of formula 4 compound are at 1:1～40:1; Temperature is-20～80 DEG C, 10～20 hours response time.
The preparation method of tafluprost 6:
Formula 5 compound obtains formula 6 compound by acetyl group hydrolysis, and acetyl group hydrolysis solvent uses isopropanol; Alkali uses the sodium isopropylate that metallic sodium and isopropanol locally produce.
Preferably, metallic sodium and the ratio of formula 5 compound are in 0.8:1～10:1, temperature-20～80 DEG C, 0.5～24 hour response time.
Such as the method that following formula prepares tafluprost 6:
With compound 1 for raw material; by Horner-Wadsworth-Emmons reaction forming side chain synthesis type 2 compound; formula 2 compound protects base to be obtained by reacting formula 3 compound through de-THP; formula 3 compound passes through acetylization reaction synthesis type 4 compound; formula 4 compound is through fluorination reaction synthesis type 5 compound, and formula 5 compound obtains tafluprost 6 by acetyl group hydrolysis.
Preferably, Horner-Wadsworth-Emmons reaction alkali used is butyl lithium, t-BuOK, LiOH H2O or Et3N/LiCl, solvent is dichloromethane, toluene or oxolane; De-THP protects base reaction to carry out in acid condition, and acid used is hydrochloric acid, acetic acid, p-methyl benzenesulfonic acid or trifluoroacetic acid, and solvent is methanol, ethanol, isopropanol or oxolane; Acetylization reaction reagent is acetic anhydride or chloroacetic chloride, and solvent is dichloromethane, dichloroethanes, chloroform, toluene or acetonitrile; In fluorination reaction, fluorination reagent is Deoxofluor, sulfur trifluoride or sulfur trifluoride morpholine; Solvent is dichloromethane, chloroform or toluene; Acetyl group hydrolysis solvent is isopropanol, and alkali uses the sodium isopropylate that metallic sodium and isopropanol locally produce.
More preferably, in Horner-Wadsworth-Emmons reaction, the mol ratio of side chain and aldehyde is 0.8:1～2.5:1, and temperature is-20～80 DEG C, 1～24 hour response time; De-THP protects the molar ratio of base reaction Chinese style 2 compound and acid at 0.1:1～0.6:1, and temperature is 0～80 DEG C, 1～24 hour response time; In acetylization reaction, acetylation reagent and the molar ratio of formula 3 compound are at 0.8:1～3:1, and temperature is-20～80 DEG C, 0.5～24 hour response time; The molar ratio of fluorination reagent and formula 3 compound is at 1:1～40:1; Temperature is-20～80 DEG C, 10～20 hours response time; The ratio of acetyl group hydrolysis metallic sodium and formula 5 compound is in 0.8:1～10:1, temperature-20～80 DEG C, 0.5～24 hour response time.
It is further preferred that in Horner-Wadsworth-Emmons reaction, the mol ratio of side chain and aldehyde is 1.2:1, and temperature is 20～30 DEG C.
Further preferably, de-THP protects base reaction temperature to be 30 DEG C.
Detailed description of the invention
Embodiment 1.
(Z)-7-((1R, 2R, 3R, 5S)-5-acetoxyl group-2-((E)-3-oxo-4-benzene oxygen but-1-ene-1-base)-3-((tetrahydrochysene-2H-pyrans-2-base) oxygen base) Pentamethylene. base) heptan-5-isopropyl gadoleate 2.
2.6 grams of 2-oxo-3-benzene oxygen propyl phosphonic acid methyl esters 7 are dissolved in 30 milliliters of toluene, add 0.42 gram of LiOH.H2O, 0.05 gram of tetrabutyl ammonium bromide,-20 DEG C are stirred 1 hour. add 5 grams of (Z)-7-((1R, 2R, 3R, 5S)-5-acetoxyl group-2-formoxyl-3-((tetrahydrochysene-2H-pyrans-2-base) oxygen base) cyclopenta) solution that heptan ,-5-isopropyl gadoleate 1 mixed with 60 milliliters of toluene, continue stirring 24 hours, TLC detects raw material 7 and remains, reactant liquor salt is washed 2 times, anhydrous sodium sulfate dries, concentration, the weak yellow liquid 4.4g. productivity 78.5%. obtaining 2 is directly used in subsequent reactions. and take sample and cross purified on silica gel, ethyl acetate/normal hexane (1:2) eluting, obtain the yellow liquid of 2.1H-NMR(CDCl3, 300MHz) and δ (ppm): 1.23 (d, 6H), 1.45-2.05(m, 13H), 2.07 (s, 3H), 2.16 (m, 1H), 2.24 (t, 2H), 2.42-2.59 (m, 1H), 2.65-2.79 (m, 1H), 3.40 (m, 1H), 3.67-3.81 (m, 1H), 3.98-4.15 (m, 1H), 4.46-4.56(m, 1H), 4.71 (d, 2H), 5.00 (m, 1H), 5.09 (m, 1H), 5.30 (m, 2H), 6.57 (dd, 1H), 6.90-7.02 (m, 4H), 7.31 (m, 2H).
Embodiment 2.
(Z)-7-((1R, 2R, 3R, 5S)-5-acetoxyl group-2-((E)-3-oxo-4-benzene oxygen but-1-ene-1-base)-3-((tetrahydrochysene-2H-pyrans-2-base) oxygen base) Pentamethylene. base) heptan-5-isopropyl gadoleate 2.
3.6 grams of 2-oxo-3-benzene oxygen propyl phosphonic acid methyl esters 7 are dissolved in 30 milliliters of dichloromethane, add 0.58 gram of butyl lithium, 0.05 gram of tetrabutyl ammonium bromide, room temperature (20～30 DEG C) stirs 1 hour. add 5 grams of (Z)-7-((1R, 2R, 3R, 5S)-5-acetoxyl group-2-formoxyl-3-((tetrahydrochysene-2H-pyrans-2-base) oxygen base) cyclopenta) solution that heptan ,-5-isopropyl gadoleate 1 mixed with 60 milliliters of dichloromethane, continue to be stirred at room temperature 15 hours, TLC detection remains without raw material 1, reactant liquor salt is washed 2 times, anhydrous sodium sulfate dries, concentration, the weak yellow liquid 5.6g. productivity 85.4%. obtaining 2 is directly used in subsequent reactions.
Embodiment 3.
(Z)-7-((1R, 2R, 3R, 5S)-5-acetoxyl group-2-((E)-3-oxo-4-benzene oxygen but-1-ene-1-base)-3-((tetrahydrochysene-2H-pyrans-2-base) oxygen base) Pentamethylene. base) heptan-5-isopropyl gadoleate 2.
6.1 grams of 2-oxo-3-benzene oxygen propyl phosphonic acid methyl esters 7 are dissolved in 45 milliliters of oxolanes, add 1.0 grams of t-BuOK, 0.05 gram of tetrabutyl ammonium bromide, 80 DEG C are stirred 1 hour. add 5 grams of (Z)-7-((1R, 2R, 3R, 5S)-5-acetoxyl group-2-formoxyl-3-((tetrahydrochysene-2H-pyrans-2-base) oxygen base) cyclopenta) solution that heptan ,-5-isopropyl gadoleate 1 mixed with 60 milliliters of oxolanes, continue stirring 1 hour, TLC detection remains without raw material 1, reactant liquor is poured onto in 200 mL of saline, extract by 50mlX4 ethyl acetate, merge organic facies, wash 2 times with salt, anhydrous sodium sulfate dries, concentration, the weak yellow liquid 4.9g. productivity 74.9%. obtaining 2 is directly used in subsequent reactions.
Embodiment 4
(Z)-7-((1R, 2R, 3R, 5S)-5-acetoxy-3-hydroxyl-2-((E)-3-oxo-4-benzene oxygen but-1-ene-1-base) cyclopenta)-5-isopropyl gadoleate in heptan 3.
The product that upper step obtains 25.6 grams dissolves with 50 milliliters of THF, adds 3 milliliters of water, 0.3 gram of acetic acid, and 80 DEG C are stirred 24 hours, and TLC remains without raw material, is poured onto 100 milliliters of saturated NaHCO3In aqueous solution, stirring is lower adds solid NaHCO3Powder generates to bubble-free, and decompression boils off major part THF, uses 100mlX3 dichloromethane extraction, merges organic facies, concentration, crosses silica gel, with ethyl acetate/normal hexane (1:2) eluting, obtain the weak yellow liquid 3.4 grams of 3. productivity 72.2%.1H-NMR(CDCl3, 300MHz) and δ (ppm): 1.23 (d, 6H), 1.63-2.03 (m, 7H), 2.08 (s, 3H), 2.16 (m, 1H), 2.26 (t, 2H), 2.54 (m, 2H), 4.06(m, 1H), 4.73 (s, 2H), 5.02 (m, 1H), 5.16 (m, 1H), 5.31 (m, 2H), 6.60 (d, 1H), 6.89-6.96 (m, 3H), 7.01 (m, 1H), 7.32 (m, 2H).
Embodiment 5
(Z)-7-((1R, 2R, 3R, 5S)-5-acetoxy-3-hydroxyl-2-((E)-3-oxo-4-benzene oxygen but-1-ene-1-base) cyclopenta)-5-isopropyl gadoleate in heptan 3.
The product that upper step obtains 25.6 grams dissolves by 100 ml methanol, 0.8 gram of p-methyl benzenesulfonic acid, and 0 degree is stirred 15 hours, and TLC remains without raw material, is poured onto 100 milliliters of saturated NaHCO3In aqueous solution, stirring is lower adds solid NaHCO3Powder generates to bubble-free, and decompression boils off major part methanol 100mlX3 dichloromethane extraction, merges organic facies, concentration, crosses silica gel, with ethyl acetate/normal hexane (1:2) eluting, obtain the weak yellow liquid 4.2 grams of 3. productivity 88.3%.
Embodiment 6
(Z)-7-((1R, 2R, 3R, 5S)-5-acetoxy-3-hydroxyl-2-((E)-3-oxo-4-benzene oxygen but-1-ene-1-base) cyclopenta)-5-isopropyl gadoleate in heptan 3.
The product that upper step obtains 24.4 grams dissolves with 50 milliliters of ethanol, adds 1 milliliter of 1N hydrochloric acid, and 30 degree are stirred 1 hour, and TLC remains without raw material, is poured onto 100 milliliters of saturated NaHCO3In aqueous solution, stirring is lower adds solid NaHCO3Powder generates to bubble-free, and decompression boils off major part ethanol, uses 100mlX3 dichloromethane extraction, merges organic facies, concentration, crosses silica gel, with ethyl acetate/normal hexane (1:2) eluting, obtain the weak yellow liquid 3.0 grams of 3. productivity 81.1%.
Embodiment 7
(Z)-7-((1R, 2R, 3R, 5S)-3,5-biacetyl oxygen base-2-((E)-3-oxo-4-benzene oxygen but-1-ene-1-base) cyclopenta)-5-isopropyl gadoleate in heptan 4.
Dissolve with 35 milliliters of dichloromethane, add 0.1 gram of DMAP and 3 milliliters of triethylamines, under nitrogen protection for 3.0 gram 3; room temperature (20～30 DEG C) adds 1.25 grams of acetic acid chlorine, stirs 15 hours, and TLC detects without raw material; washing by 100 mL of saline, 0.5N dilute hydrochloric acid is washed, NaHCO3Aqueous solution is washed, and salt is washed, and concentration is crossed silica gel, with ethyl acetate/normal hexane (1:2) eluting, obtained the weak yellow liquid 3.6 grams of 4. productivity 91.0%.1H-NMR(CDCl3,300MHz)δ(ppm):1.23(d,6H),1.63-1.86(m,4H),1.98(s,3H),1.99-2.08(m,3H),2.09(s,3H),2.16(m,1H),2.24(t,2H),2.57(m,1H),2.75(m,1H),4.73(s,2H),5.01(m,1H),5.13(m,1H),5.34(m,2H),6.51(d,1H),6.89-7.12(m,4H),7.32(m,2H).
Embodiment 8
(Z)-7-((1R, 2R, 3R, 5S)-3,5-biacetyl oxygen base-2-((E)-3-oxo-4-benzene oxygen but-1-ene-1-base) cyclopenta)-5-isopropyl gadoleate in heptan 4.
4.2 gram 3 with 35 milliliters of pyridinium dissolution; adding 0.1 gram of DMAP, nitrogen protection borehole cooling, to-20 DEG C, adds 4.3 ml acetic anhydride; stir 24 hours; TLC detects without raw material, is poured onto in 100 milliliters of frozen water, extracts by 50mlX4 ethyl acetate; merge organic facies; washing with water, 0.5N dilute hydrochloric acid is washed, NaHCO3Aqueous solution is washed, and salt is washed, and concentration is crossed silica gel, with ethyl acetate/normal hexane (1:2) eluting, obtained the weak yellow liquid 3.5 grams of 4. productivity 76.5%.
Embodiment 9
(Z)-7-((1R, 2R, 3R, 5S)-3,5-biacetyl oxygen base-2-((E)-3-oxo-4-benzene oxygen but-1-ene-1-base) cyclopenta)-5-isopropyl gadoleate in heptan 4.
Dissolve with 35 milliliters of acetonitriles for 3.4 gram 3; add 0.1 gram of DMAP and 4 milliliters of pyridines; adding 1.7 grams of acetic acid chlorine under nitrogen protection, 80 DEG C are stirred 0.5 hour, and TLC detects without raw material; it is poured onto in 100 milliliters of frozen water; extract by 50mlX4 ethyl acetate, merge organic facies, wash with water; 0.5N dilute hydrochloric acid is washed, NaHCO3Aqueous solution is washed, and salt is washed, and concentration is crossed silica gel, with ethyl acetate/normal hexane (1:2) eluting, obtained the weak yellow liquid 2.66 grams of 4. productivity 71.8%.
Embodiment 10
(Z)-7-((1R, 2R, 3R, 5S)-3,5-biacetyl oxygen base-2-((E)-3,3-two fluoro-4-benzene oxygen but-1-ene-1-base) cyclopenta)-5-isopropyl gadoleate in heptan 5
Dissolving with 30 milliliters of dichloromethane for 2.6 gram 4, add 5.3 milliliters of double; two (2-methoxyethyl) amino sulfur trifluorides (Deoxofluro), room temperature (20～30 DEG C) stirs 72 hours, is poured onto 100 milliliters of saturated NaHCO3In aqueous solution, point phase after stirring, aqueous phase, with 50 milliliters of dichloromethane extraction, after merging organic facies, concentrates, crosses silica gel, with ethyl acetate/normal hexane (1:3) eluting, obtain the yellow liquid 2.1 grams of 5. productivity 77.4%.1H-NMR(CDCl3,300MHz)δ(ppm):1.23(d,6H),1.69-1.82(m,5H),1.96-2.06(m.2H),1.99(s,3H),2.08(s,3H),2.12-2.22(m,1H),2.24(t,2H),2.58(m,1H),2.69(m,1H),4.20(t,2H),4.98(m,1H),5.02(m,1H),5.13(t,1H),5.34(m,2H),5.84(dt,1H),6.13(m,1H),6.92(d,2H),7.03(t,1H),7.32(t,2H).
Embodiment 11
(Z)-7-((1R, 2R, 3R, 5S)-3,5-biacetyl oxygen base-2-((E)-3,3-two fluoro-4-benzene oxygen but-1-ene-1-base) cyclopenta)-5-isopropyl gadoleate in heptan 5
Dissolving with 30 milliliters of toluene, add 1.2 grams of sulfur trifluoride morpholines for 3.5 gram 4,80 DEG C are stirred 10 hours, are poured onto 100 milliliters of saturated NaHCO3In aqueous solution, point phase after stirring, aqueous phase, with 50 milliliters of methylbenzene extraction, after merging organic facies, concentrates, crosses silica gel, with ethyl acetate/normal hexane (1:3) eluting, obtain the yellow liquid 2.13 grams of 5. productivity 58.6%.
Embodiment 12
(Z)-7-((1R, 2R, 3R, 5S)-3,5-biacetyl oxygen base-2-((E)-3,3-two fluoro-4-benzene oxygen but-1-ene-1-base) cyclopenta)-5-isopropyl gadoleate in heptan 5
Dissolving with 30 milliliters of toluene, add 1.2 grams of sulfur trifluorides for 3.5 gram 4 ,-20 DEG C are stirred 200 hours, are poured onto 100 milliliters of saturated NaHCO3In aqueous solution, point phase after stirring, aqueous phase, with 50 milliliters of methylbenzene extraction, after merging organic facies, concentrates, crosses silica gel, with ethyl acetate/normal hexane (1:3) eluting, obtain the yellow liquid 2.47 grams of 5. productivity 68.6%.
Embodiment 13
(Z)-7-((1R, 2R, 3R, 5S)-3,5-dihydroxy-2-((E)-3,3-two fluoro-4-benzene oxygen but-1-ene-1-base) cyclopenta)-5-isopropyl gadoleate 6 in heptan (tafluprost)
Dissolve with 10 milliliters of isopropanols for 2.1 gram 5, add the sodium isopropylate solution being made into by 5 milliliters of isopropanols and 0.3 gram of metallic sodium, 50 DEG C are stirred 4 hours, TLC remains without raw material. reactant liquor is poured onto in the aqueous citric acid solution of 30 milliliter 3%, decompression boils off major part isopropanol, extract by 20mlX3 ethyl acetate, merge organic facies, use NaHCO3Solution is washed, column chromatography after concentration, affords 1.5 grams of tafluprosts 6, productivity 84.7%. with ethyl acetate/normal hexane (1:1)1H-NMR(CDCl3,300MHz)δ(ppm):1.23(d,6H),1.57-1.70(m,3H),1.84(d,1H),2.04-2.15(m.4H),2.25(t,2H),2.28-2.36(m,1H),2.42-2.49(m,1H),4.01(m,1H),4.20(m,3H),4.99(m,1H),5.38(m,2H),5.79(dt,1H),6.10(m,1H),6.92(d,2H),7.01(t,1H),7.30(t,2H).
Embodiment 14
(Z)-7-((1R, 2R, 3R, 5S)-3,5-dihydroxy-2-((E)-3,3-two fluoro-4-benzene oxygen but-1-ene-1-base) cyclopenta)-5-isopropyl gadoleate 6 in heptan (tafluprost)
Dissolve with 10 milliliters of isopropanols for 2.1 gram 5, add the sodium isopropylate solution being made into by 10 milliliters of isopropanols and 0.8 gram of metallic sodium,-20 DEG C of degree stir 24 hours, TLC remains without raw material. reactant liquor is poured onto in the aqueous citric acid solution of 30 milliliter 3%, decompression boils off major part isopropanol, extract by 20mlX3 ethyl acetate, merge organic facies, use NaHCO3Solution is washed, column chromatography after concentration, affords 1.6 grams of tafluprosts 6, productivity 92.5%. with ethyl acetate/normal hexane (1:1)
Embodiment 15
(Z)-7-((1R, 2R, 3R, 5S)-3,5-dihydroxy-2-((E)-3,3-two fluoro-4-benzene oxygen but-1-ene-1-base) cyclopenta)-5-isopropyl gadoleate 6 in heptan (tafluprost)
Dissolve with 10 milliliters of isopropanols for 2.1 gram 5, add the sodium isopropylate solution being made into by 10 milliliters of isopropanols and 0.5 gram of metallic sodium, 80 DEG C are stirred 0.5 hour, TLC remains without raw material. reactant liquor is poured onto in the aqueous citric acid solution of 30 milliliter 3%, decompression boils off major part isopropanol, extract by 20mlX3 ethyl acetate, merge organic facies, use NaHCO3Solution is washed, column chromatography after concentration, affords 1.3 grams of tafluprosts 6, productivity 73.7%. with ethyl acetate/normal hexane (1:1)

Claims (7)

1. the preparation method of formula 3 compound, it is characterised in that:
Formula 2 compound is sloughed THP in acid condition and is protected base to obtain formula 3 compound, and acid is selected from hydrochloric acid, acetic acid, p-methyl benzenesulfonic acid or trifluoroacetic acid; Solvent selected from methanol, ethanol, isopropanol or oxolane; The molar ratio of formula 2 compound and acid is 0.1:1～0.6:1, and temperature is 0～80 DEG C, 1～24 hour response time.
2. the preparation method of formula 3 compound according to claim 1, it is characterised in that temperature is 30 DEG C.
3. the preparation method of formula 4 compound, it is characterised in that:
Formula 3 compound passes through acetylization reaction synthesis type 4 compound, and acetylation reagent is selected from acetic anhydride or chloroacetic chloride; Solvent is selected from pyridine, dichloromethane, dichloroethanes, chloroform, toluene or acetonitrile; The molar ratio of acetylation reagent and formula 3 compound is at 0.8:1～3:1, and temperature is-20～80 DEG C, 0.5～24 hour response time.
4. the preparation method of a tafluprost 6, it is characterised in that
In Horner-Wadsworth-Emmons reaction, the mol ratio of side chain and aldehyde is 0.8:1～2.5:1, and temperature is-20～80 DEG C, 1～24 hour response time; De-THP protects the molar ratio of base reaction Chinese style 2 compound and acid at 0.1:1～0.6:1, and temperature is 0～80 DEG C, 1～24 hour response time; In acetylization reaction, acetylation reagent and the molar ratio of formula 3 compound are at 0.8:1～3:1, and temperature is-20～80 DEG C, 0.5～24 hour response time; The molar ratio of fluorination reagent and formula 4 compound is at 1:1～40:1; Temperature is-20～80 DEG C, 10～20 hours response time; The ratio of acetyl group hydrolysis metallic sodium and formula 5 compound is in 0.8:1～10:1, temperature-20～80 DEG C, 0.5～24 hour response time.
5. the preparation method of tafluprost 6 according to claim 4, it is characterised in that it is 1.2:1 that Horner-Wadsworth-Emmons reacts the mol ratio that mol ratio is side chain and aldehyde of side chain and aldehyde, and temperature is 20～30 DEG C.
6. the preparation method of tafluprost 6 according to claim 5, it is characterised in that de-THP protects base reaction temperature to be 30 DEG C.
7. the application according to the preparation method one of claim 1-6 Suo Shu, in the synthesis preparing MISOPROSTOL prostatitis element, travoprost, latanoprost, 16-phenoxy group prostatitis element.
CN201410037416.0A 2014-01-26 2014-01-26 A kind of method synthesizing tafluprost Active CN103804195B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201410037416.0A CN103804195B (en) 2014-01-26 2014-01-26 A kind of method synthesizing tafluprost

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410037416.0A CN103804195B (en) 2014-01-26 2014-01-26 A kind of method synthesizing tafluprost

Publications (2)

Publication Number Publication Date
CN103804195A CN103804195A (en) 2014-05-21
CN103804195B true CN103804195B (en) 2016-06-15

Family

ID=50701636

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201410037416.0A Active CN103804195B (en) 2014-01-26 2014-01-26 A kind of method synthesizing tafluprost

Country Status (1)

Country Link
CN (1) CN103804195B (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1187486A (en) * 1996-12-26 1998-07-15 旭硝子株式会社 Difluoroprostaglundin Derivatives and their use
CN1774417A (en) * 2001-05-31 2006-05-17 梵泰克实验室有限公司 A new process for the preparation of 17-phenyl-18, 19, 20-trinor-PGF2A and its derivatives
CN103570549A (en) * 2013-10-11 2014-02-12 天泽恩源（天津）医药技术有限公司 Novel method for synthesizing Tafluprost

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1187486A (en) * 1996-12-26 1998-07-15 旭硝子株式会社 Difluoroprostaglundin Derivatives and their use
US5985920A (en) * 1996-12-26 1999-11-16 Asahi Glass Company Ltd. Difluoroprostaglandin derivatives and their use
CN1774417A (en) * 2001-05-31 2006-05-17 梵泰克实验室有限公司 A new process for the preparation of 17-phenyl-18, 19, 20-trinor-PGF2A and its derivatives
CN103570549A (en) * 2013-10-11 2014-02-12 天泽恩源（天津）医药技术有限公司 Novel method for synthesizing Tafluprost

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Synthesis of the highly potent prostanoid FP receptor agonist, AFP-168: a novel 15-deoxy-15,15-difluoroprostaglandin F2α derivative;Yasushi Matsumura;《Tetrahedron Letters》;20040209;第45卷(第7期);1527-1529 *

Also Published As

Publication number Publication date
CN103804195A (en) 2014-05-21

Similar Documents

Publication Publication Date Title
CN108314639B (en) Compound (E) -3-(1- methylpyrrolidin- 2- yl)-acrylic acid hydrochloride and synthetic method
US8772544B2 (en) Process for the production of bimatoprost
CN105254589B (en) A method of preparing heart failure drugs intermediate
CN103570549B (en) A kind of method of synthesizing tafluprost
EP2143712A1 (en) Improved Process for the Production of Prostaglandins and Prostaglandin Analogs
CN104478976A (en) Preparation method for sofosbuvir
JP5815507B2 (en) Process for purification of 1-methylpyrazole-4-carboxylic acid ester
CN104140410A (en) Preparation method of lubiprostone
CN103804195B (en) A kind of method synthesizing tafluprost
CN107501542A (en) A kind of preparation method of Amino End Group polyethylene glycol t-butyl carbamate
CN109415405A (en) The method for preparing shellfish cholic acid difficult to understand
CN107540588A (en) The preparation method of paricalcitol
CN104163787A (en) Preparation methods of Atazanavir and sulfate of Atazanavir
CN103421023B (en) A kind of synthesis technique of CCI-779
EP2925720B1 (en) Process for the preparation of travoprost
CN105367391B (en) A kind of preparation method of the trimethoxy-ethane of 2 chlorine 1,1,1
EP4324819A2 (en) New intermediates for the vitamin a synthesis
CN108503619A (en) The synthetic method of 1R, 2R, 3R- substituted cyclopentanone class compound
CN103709132A (en) Method for preparing nebivolol midbody
CN109704933A (en) A kind of sex pheromone of diamond back moth preparation method
CN105254537A (en) Preparation method of Nalpha-fluorenylmethoxycarbonyl-glutamine tert-butyl ester
CN103764639B (en) For the preparation of the method for derivative of fatty acid
KR102069205B1 (en) Process for Preparing Latanoprostene bunod and Intermediate Therefor
CN106986908B (en) The preparation method of betamethasone
CN109761868A (en) A kind of synthetic method of optical voidness cloprostenol

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: 301700 Tianjin New Technology Industrial Park, Wuqing Development Zone, Sau Sau Road, No. 10

Applicant after: TIEN (TIANJIN) PHARMACEUTICAL CO.,LTD.

Address before: 301700 Tianjin Fuyuan Wuqing Development Zone Wuqing Road No. 18 505-23 (central office)

Applicant before: TIEN (TIANJIN) PHARMACEUTICAL CO.,LTD.

Address after: 301700 Tianjin Fuyuan Wuqing Development Zone Wuqing Road No. 18 505-23 (central office)

Applicant after: TIEN (TIANJIN) PHARMACEUTICAL CO.,LTD.

Address before: 301700 Tianjin Fuyuan Wuqing Development Zone Wuqing Road No. 18 505-23 (central office)

Applicant before: TIEN (TIANJIN) PHARMACEUTICAL CO.,LTD.

COR Change of bibliographic data
C14 Grant of patent or utility model
GR01 Patent grant